Anastazia Kei, Moses Elisaf
As the focus of cardiovascular risk management is extending beyond statins and low density lipoprotein cholesterol (LDL-C) management, a number of therapeutic options has been proposed for low high density lipoprotein cholesterol (HDL-C) and high triglycerides levels. Fibrates have been shown to substantially reduce triglycerides and increase HDL-C levels, comprising a reasonable second-line treatment for mixed dyslipidemia. Moreover, fenofibrate combined with a standard statin dose is a well tolerated therapy, while data supporting the fenofibrate-associated reduction of diabetic retinopathy exist. The benefits of fenofibrate regarding cardiovascular disease and its potential role in combination therapy require further confirmation.
Keywords: fenofibrate, mixed dyslipidemia, hypertriglyceridemia, diabetic dyslipidemia